Panacea Biotec Awarded $35.65 Million UNICEF Contract for bOPV Supply

Panacea Biotec has secured a significant contract with UNICEF for the supply of bivalent oral polio vaccine (bOPV). The contract, valued at approximately $35.65 million (₹315 crore), covers deliveries scheduled for Q2 CY2026 and CY2027, with a long-term agreement (LTA) running from April 1, 2026, to March 31, 2030. This contract marks a major milestone for the company in the global vaccine supply sector.

Overview of the Contract Received by Panacea Biotec

The awarded contract entails the supply of bOPV in both 10-vial and 20-vial presentations to UNICEF. The deliveries are scheduled to occur during Q2 CY2026 and CY2027, and the agreement will span from April 1, 2026, to March 31, 2030. As per standard practice, UNICEF will disclose the supplier name, vaccine, award duration, total value, and prices per presentation per year on its official website for transparency.

Contract Value and Scope

The total value of the contract is approximately $35.65 million, which is equivalent to ₹315 crore. This sum covers UNICEF's vaccine procurement needs during the specified periods. The contract is a vaccine supply order for bOPV to an international entity, with fulfilment dependent on UNICEF's purchase orders issued from time to time within the agreement’s timeline.

Execution Timeline

The execution of this agreement will occur in Q2 CY2026 and CY2027, aligning with UNICEF’s procurement plan. The long-term agreement, valid from April 1, 2026, to March 31, 2030, will ensure consistent supply and manufacturing scheduling in line with UNICEF's needs. Periodic pricing and operational disclosures will be made by UNICEF each award year and product presentation as part of their transparency regime.

Read More: India’s Pharma Exports to Cross $30 Billion; Domestic Market to Double by 2030!

Panacea Biotec Share Price Performance

On October 3, 2025, Panacea Biotec share price opened at ₹403.00 on NSE, above the previous close of ₹401.00. During the day, it surged to ₹425.00 and dipped to ₹398.50. The stock closed at ₹415.25 by the end of the day. The stock registered a significant gain of 3.55%.

Over the past week, it has moved up by 2.62%, over the past month, it has moved up by 1.91%, and over the past 3 months, it has declined by 0.69%.

Conclusion

Panacea Biotec’s long-term agreement with UNICEF to supply bOPV is a significant achievement for the company. With a value of US$ 35.65 million (₹315 crore), this contract solidifies Panacea Biotec's position in the global vaccine supply chain and opens doors for continued growth in the international market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.